156 related articles for article (PubMed ID: 29609559)
1. Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer.
Yang L; Jiang X; Yan H; Li Y; Zhen H; Chang B; Kariminia S; Li Q
BMC Gastroenterol; 2018 Apr; 18(1):43. PubMed ID: 29609559
[TBL] [Abstract][Full Text] [Related]
2. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis.
Cho YH; Yoon SY; Kim SN
Cancer Res Treat; 2017 Jan; 49(1):255-262. PubMed ID: 27188198
[TBL] [Abstract][Full Text] [Related]
4. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
Hironaka S; Ueda S; Yasui H; Nishina T; Tsuda M; Tsumura T; Sugimoto N; Shimodaira H; Tokunaga S; Moriwaki T; Esaki T; Nagase M; Fujitani K; Yamaguchi K; Ura T; Hamamoto Y; Morita S; Okamoto I; Boku N; Hyodo I
J Clin Oncol; 2013 Dec; 31(35):4438-44. PubMed ID: 24190112
[TBL] [Abstract][Full Text] [Related]
5. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer.
Kawakami T; Machida N; Yasui H; Kawahira M; Kawai S; Kito Y; Yoshida Y; Hamauchi S; Tsushima T; Todaka A; Yokota T; Yamazaki K; Fukutomi A; Onozawa Y
Cancer Chemother Pharmacol; 2016 Oct; 78(4):809-14. PubMed ID: 27566700
[TBL] [Abstract][Full Text] [Related]
7. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Thuss-Patience PC; Kretzschmar A; Bichev D; Deist T; Hinke A; Breithaupt K; Dogan Y; Gebauer B; Schumacher G; Reichardt P
Eur J Cancer; 2011 Oct; 47(15):2306-14. PubMed ID: 21742485
[TBL] [Abstract][Full Text] [Related]
8. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial).
Higuchi K; Tanabe S; Shimada K; Hosaka H; Sasaki E; Nakayama N; Takeda Y; Moriwaki T; Amagai K; Sekikawa T; Sakuyama T; Kanda T; Sasaki T; Azuma M; Takahashi F; Takeuchi M; Koizumi W;
Eur J Cancer; 2014 May; 50(8):1437-45. PubMed ID: 24560487
[TBL] [Abstract][Full Text] [Related]
9. Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials.
Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
Int J Cancer; 2013 Jan; 132(2):E66-73. PubMed ID: 22890856
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
[TBL] [Abstract][Full Text] [Related]
11. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis.
Guo X; Zhao F; Ma X; Shen G; Ren D; Zheng F; Du F; Wang Z; Ahmad R; Yuan X; Zhao J; Zhao J
BMC Cancer; 2019 Nov; 19(1):1125. PubMed ID: 31747911
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer.
Makiyama A; Arimizu K; Hirano G; Makiyama C; Matsushita Y; Shirakawa T; Ohmura H; Komoda M; Uchino K; Inadomi K; Arita S; Ariyama H; Kusaba H; Shinohara Y; Kuwayama M; Kajitani T; Oda H; Esaki T; Akashi K; Baba E
Gastric Cancer; 2018 May; 21(3):464-472. PubMed ID: 28799048
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a meta-analysis of randomized controlled trials.
Zeng C; Zhou H; Wei Y; Wang L; Xie H; Yao W
Chin Med J (Engl); 2014; 127(5):951-6. PubMed ID: 24571893
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes.
Nishimura T; Iwasa S; Nagashima K; Okita N; Takashima A; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Boku N
Gastric Cancer; 2017 Jul; 20(4):655-662. PubMed ID: 27858180
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials.
Wang DL; Gu DY; Huang HY; Xu Z; Chen JF
World J Gastroenterol; 2010 Dec; 16(46):5889-94. PubMed ID: 21155012
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.
Sym SJ; Hong J; Park J; Cho EK; Lee JH; Park YH; Lee WK; Chung M; Kim HS; Park SH; Shin DB
Cancer Chemother Pharmacol; 2013 Feb; 71(2):481-8. PubMed ID: 23192279
[TBL] [Abstract][Full Text] [Related]
17. [Combination of irinotecan and Mitomycin C as second-line chemotherapy for patients with unresectable advanced or recurrent gastric cancer in clinical practice].
Miyamoto H; Yoshida M; Yamanouchi T; Kanda K; Zinnouchi K; Kiyozumi T; Koba I; Akashi R; Sagara K
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1293-7. PubMed ID: 19692768
[TBL] [Abstract][Full Text] [Related]
18. Doublet Versus Single Agent as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis of 10 Randomized Controlled Trials.
Zhang Y; Ma B; Huang XT; Li YS; Wang Y; Liu ZL
Medicine (Baltimore); 2016 Feb; 95(8):e2792. PubMed ID: 26937908
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer].
Kwon HJ; Park MI; Park SJ; Moon W; Kim SE; Lee HW; Choi YJ; Kim JH
Korean J Gastroenterol; 2015 Jul; 66(1):10-6. PubMed ID: 26194124
[TBL] [Abstract][Full Text] [Related]
20. Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.
Kang BW; Kim JG; Kwon OK; Chung HY; Yu W
World J Gastroenterol; 2014 May; 20(18):5396-402. PubMed ID: 24833869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
